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Sheehan’s syndrome remains a frequent obstetric complication with an uncertain pathophysiology. We aimed to assess the
incidence of hypopituitarism (≥2 hormonal axis impairment) within the ﬁrst six postchildbirth months and to determine the
existence of anti-pituitary antibodies. From 2015 to 2017, adult pregnant women, who developed moderate to severe
postpartum hemorrhage (PPH), were consecutively included in the study. Pituitary function was assessed 4 and 24 weeks after
PPH. At the end of the study, anti-pituitary antibodies were assessed. Twenty women completed the study. Mean age was 26.35
(±5.83) years. The main etiology for severe PPH was uterine atony (65%) which resulted mostly in hypovolemic shock grades
III-IV. Within the ﬁrst four weeks after delivery, 95% of patients had at least one hormonal pituitary aﬀected and 60% of the
patients fulﬁlled diagnostic criteria for hypopituitarism. At the end of the study period, ﬁve patients (25%) were diagnosed with
hypopituitarism (GH and cortisol axes aﬀected). Anti-pituitary antibodies were negative in all patients. At 6 months follow-up,
one in every four women with a history of moderate-to-severe PPH was found with asymptomatic nonautoimmune-mediated
hypopituitarism. The role of autoimmunity in Sheehan’s syndrome remains uncertain. Further studies are needed to improve
the remaining knowledge gaps.
1. Introduction
Sheehan’s syndrome remains a frequent obstetric complica-
tion in emergent and developed countries that to date still
reports a relatively high prevalence of moderate to severe
postpartum hemorrhage (PPH) [1–4]. Sheehan’s syndrome
has been usually described to aﬀect pregnant woman after
moderate to profound hypovolemic shock throughout deliv-
ery. However, it is usually diagnosed months to years after
the hemorrhagic event [5, 6]. Due to its delayed diagnosis,
clinical presentation (which usually impairs quality of life),
and potentially life-threatening complications (e.g. coma or
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death), Sheehan’s syndrome still remains important to preg-
nant women, clinicians, and public health services around
the world [6].
The pathophysiology of Sheehan’s syndrome has been
classically attributed to a transient hypoperfusion that
provokes infarction, necrosis, and consequent dysfunction
in a physiologically enlarged pituitary gland (due to preg-
nancy) [5, 7–9]. The next rational pathophysiological step
would be an immediate hypopituitarism; however, this is
rarely the case. De facto, Sheehan’s syndrome’s reported inci-
dence in patients, who suﬀered PPH, ranges from 0 to 30%
[10–12]. Previous studies that have prospectively assessed
pituitary function shortly after a PPH event have had small
sample size or a short follow-up period. Consequently, their
results are diﬃcult to interpret [10, 11]. Moreover, not every
woman who suﬀers PPH develops Sheehan’s syndrome and
when they do, it manifests within a wide spectrum of time
(from months to years), suggesting that there are other fac-
tors that inﬂuence its appearance. Recently, several studies
have assessed the role that autoimmunity could have in the
pathophysiology of Sheehan’s syndrome [13–16]. De Bellis
et al. retrospectively detected anti-hypothalamic antibodies
and anti-pituitary antibodies in the serum of patients diag-
nosed with Sheehan’s syndrome (40% and 35%, resp.) [15].
However, because these autoantibodies were found years
after the disease was established, their role in the pathophys-
iology of Sheehan’s syndrome remains uncertain.
Consequently, we decided to conduct this prospective
study in patients who suﬀered moderate to severe PPH with
the primary objective of assessing the incidence of hypopitu-
itarism within the ﬁrst six months postchildbirth and to
determine the existence of anti-pituitary antibodies. Second-
ary endpoints were to correlate clinical variables with hemor-
rhage intensity and pituitary dysfunction.
2. Patients and Methods
2.1. Patient Population. After the Institutional Review
Board and Ethics Committee from our University approved
the study protocol, we began recruitment. Written informed
consent was obtained from all participants before enroll-
ment. Women≥ 18 years old who developed PPH in the
Obstetric Unit of the University Hospital “Dr. Jose E.
Gonzalez” were consecutively invited to participate in the
study. PPH was deﬁned as having one or more of the follow-
ing criteria: (a) postvaginal partum blood loss≥ 1000ml, (b)
postcesarean partum blood loss≥ 1500ml, (c) hypovolemic
shock grade III or IV, (d) hysterectomy due to unstoppable
bleeding, and (e) hemoglobin decrease≥ 3 g per liter immedi-
ately after delivery. Patients with a past medical history of
any thyroid disease, suprarenal abnormalities, pituitary mal-
function, or active tuberculosis were excluded from the study.
2.2. Study Protocol. All patients were recruited at bedside
immediately (≤3 hours) after the PPH event. A complete
medical clinical history and baseline anthropometric mea-
sures were assessed. Data regarding the PPH’s characteristics
as well as the newborns’ vital signs and APGAR scores were
also documented. Because of the association between
hypopituitarism and diabetes insipidus, monitoring of the
liquids’ input and output was closely followed during their
hospitalization period. Before their discharge, patients were
instructed to look for symptoms related to hypopituitarism
as well as diabetes insipidus. On follow-up, patients were
reassessed four and 24–28 weeks after the PPH event in order
to undergo clinical assessment and pituitary dynamic testing.
Between visits, patients were contacted via telephone every
four weeks in order to detect the appearance of symptoms
related to hypopituitarism (e.g., agalactia, amenorrhea,
impaired mental status, and fatigue) and diabetes insipidus
(e.g., thirst and an excessive amount of urine). Hypopituita-
rism was diagnosed when two or more pituitary hormonal
axes were impaired. Enhanced magnetic resonance imaging
(MRI) of the pituitary gland was obtained from patients diag-
nosed with hypopituitarism. Anti-pituitary antibodies were
assessed at the end of the study.
2.3. Measurements. Clinical data regarding pregnant women
and newborns’ vital signs, APGAR score, hemorrhage
quantiﬁcation, infused solutions, and red blood cell units
transfused at the time of the event were taken from a secured
medical record. On every follow-up visit, patients’weight and
height were determined on a calibrated Seca 700 scale and
stadiometer (TAQ Sistemas Médicos, S.A. de C.V., Mexico
City, Mexico), respectively, in order to calculate insulin dos-
age for the dynamic pituitary testing (0.1 IU of regular insulin
per kilogram).
2.3.1. Pituitary Dynamic Tests.After an eight-hour fast, blood
samples were drawn to obtain baseline glucose, cortisol,
thyroid-stimulating hormone (TSH), free T4, total T3, total
T4, growth hormone, prolactin, follicle-stimulating hormone
(FSH), luteinizing hormone (LH), and estradiol determina-
tions. Additional blood was centrifuged, and the obtained
serum was stored in aliquots and frozen at −20°C for later
processing and autoantibody detection. Next, we adminis-
trated leuprolide (100μg) to stimulate FSH and LH secretion,
TRH (200μg) to stimulate TSH and prolactin secretion, and
regular insulin 0.1 IU/kg to trigger hypoglycemia (glucose
≤45mg/dl) and stimulate growth hormone (GH) and
ACTH/cortisol secretion. Blood samples were taken at
minutes 0, 15, 30, 60, and 90 after the triple bolus administra-
tion. If the glucose levels failed to decrease below 45mg/dl
with the ﬁrst insulin dose, a second dose was administrated.
All samples were frozen and assessed twice at the same time
at the end of the study. The glucose oxidase method was used
to assess fasting plasma glucose (Stat-Fax Spectrophotome-
ter, Awareness Technology, Palm City Fl.); intra-assay and
interassay coeﬃcients of variation (CV) were 1.4% and
0.6%, respectively. FSH, LH, prolactin, TSH, total T4, free
T4, and cortisol were measured using electrochemilumines-
cence in a Cobas® 6000 e601 analyzer series (Roche,
Germany). Intra-assay and interassay CV for the diﬀerent
hormones were 2.8% and 4.5%, respectively, for FSH, 1.2%
and 2.2%, respectively, for LH, 1.7% and 2.0%, respectively,
for prolactin, 3% and 7.2%, respectively, for TSH, 1.8% and
4.2%, respectively, T4, 5% and 6.3%, respectively, for free
T4, 1.7% and 2.8%, respectively, for cortisol. GH and total
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T3 were measured using the electrochemiluminescence
method in an IMMULITE® 1000 Immunoassay System
(Siemens, Germany); intra-assay and inter-assay CV were
6.5% and 6.2%, respectively, for GH and 3.9% and 5.3%,
respectively, for T3.
A normal response to the pituitary dynamic test was con-
sidered as follows: (a) a >2-fold and a >1.5-fold increase for
LH and FSH levels, respectively, (b) a peak TSH of >2.5-fold
or a >5mU/l increase in addition to normal free T4 levels
(>0.7 ng/dl), (c) a 2.5-fold increase in serum prolactin levels,
(d) a peak cortisol response of >18μg/dl or a >5μg/dl
increase, and (e) a GH peak of >5μg/l. If two or more
axes were impaired, hypopituitarism was diagnosed [17].
A diagnosis of secondary hypothyroidism was made in
the absence of 2.5-fold increase or >5μU/l increase in
TSH levels [17, 18]. Likewise, we considered that prolactin
secretion was altered if the pituitary dynamic tests’ normality
criteria were not met [17].
2.3.2. Detection of Anti-Pituitary Antibodies by Western Blot.
Anti-pituitary antibodies were determined by Western blot.
A total of 15 patients with previously conﬁrmed Sheehan’s
syndrome and ﬁve with lymphocytic hypophysitis donated
serum samples, which were used as positive controls. Like-
wise, serum samples of 10 healthy men and women not
related to the study participants were used as negative con-
trols. All samples were assessed twice and at the same time
at the end of the planned follow-up. Human pituitary protein
lysates and gamma enolase recombinant protein were used as
target antigens for anti-pituitary antibody detection. Human
embryonic kidney (HEK-293) cell protein lysates were used
as negative control.
HEK-293 cell line (#CRL-1573) was obtained from the
American Type Culture Collection (Manassas, VA, USA).
HEK-293 cells were cultured in advanced Dulbecco’s
modiﬁed Eagle medium supplemented with 4% heat-
inactivated fetal calf serum, 2mM L-glutamine, and 100U/
ml penicillin/streptomycin (all from Cellgro, Mediatech
Inc., Manassas, VA, USA). Human pituitary samples were
donated by the Forensic Department of our University and
were collected following institutional guidelines and snap
frozen in liquid nitrogen. Subsequently, human pituitary
samples and HEK-293 cells were processed with Proteo-
JET Mammalian Cell lysis Reagent (#K0301; Fermentas,
Waltham, MA, USA) according to the manufacturer’s
instructions. The extracted HEK-293 cells and human pitui-
tary protein samples as well as gamma enolase recombinant
proteins (#N2175; US Biological, Salem, MA, USA) were sub-
jected to denaturing electrophoresis in 12% SDS-PAGE gels.
Proteins were transferred to PVDF membranes and then
blocked for 1 hour with 10% bovine serum albumin (BSA)
(#A1311; US Biological, Salem, MA, USA) in Tris-buﬀered
saline and Tween 20 (TBST) (135mM NaCl, 2.7mM KCl,
24.8mM Tris-HCl, 0.05% Tween 20, pH7.4).
Afterwards, patients’ serum and controls’ serum were
diluted at 1 : 50 concentration in 0.3% BSA in TBST buﬀer
solution. The diluted serum samples were incubated with
the membranes overnight. The membranes were washed
with TBST and incubated for 2 hours with a horseradish
peroxidase-conjugated goat anti-human IgG antibody
(sc-2453; Santa Cruz Biotechnology Inc., Dallas, TX, USA)
diluted at 1 : 5000. The gamma enolase recombinant protein
was detected with a mouse anti-γ enolase antibody (sc-
21738; Santa Cruz Biotechnology Inc., Dallas, TX, USA)
diluted at 1 : 500 and then incubated for two hours with a
horseradish peroxidase-conjugated rabbit anti-mouse anti-
body (#A9044; Sigma-Aldrich; Merck Millipore) diluted at
1 : 10,000. Signal detection was performed using Super Signal
West Pico Chemiluminescent Substrate (#34080; Pierce
Biotechnology; Thermo Fisher Scientiﬁc Inc.), and the
membranes were scanned on a C-DiGit Scanner Model
3600 (Li-cor, Lincoln, NE, USA).
2.4. Imaging Study. Enhanced MRI of the pituitary gland was
performed in a General Electric Sigma Excite 1.5T MR scan-
ner (GE Medical Systems). Two experienced neuroradiolo-
gists, separately and independently, interpreted the images.
Empty sella (complete or partial) and any other structural
lesions that could explain hypopituitarism were particularly
looked for.
2.5. Statistical Analysis. Continuous variables are reported as
means and standard deviation. Categorical variables are
reported as percentages and frequencies. Normality was
studied using the Shapiro Wilk test. Student’s t-test and the
Mann–Whitney U test were used to compare continuous
variables according to normality. Categorical variables were
compared using a Pearson’s χ2 test or Fisher’s exact test for
2× 2 tables. A P value≤ 0.05 was considered statistically
signiﬁcant. Patients who failed to complete follow-up were
not analyzed. The statistical analysis was performed using
IBM SPSS Statistics 20.0 (IBM Corp., Armonk, NY).
3. Results
3.1. Study Population. Between March 2015 and January
2017, a total of 23 patients were included in the study. Of
these, 20 women (86.7%) completed the study. Of the three
women that left the study, two were lost to follow-up for no
clear reason (despite eﬀorts to contact them) and one was
excluded due to a new pregnancy. Table 1 shows the overall
patients’ baseline characteristics. Mean age was 26.35
(±5.83) years. The main etiology for severe PPH was uter-
ine atony (65%) followed by vaginal tearing (15%). Most
patients presented at least grades III-IV of shock (75%).
There were no diﬀerences, in any of the baseline clinical
characteristics, between patients with hypopituitarism and
normal pituitary function.
3.2. Dynamic Pituitary Tests. Within the ﬁrst 4 weeks after
delivery, 19 out of 20 patients (95%) had at least one
hormonal pituitary axis aﬀected and 60% (12/20) of the
patients fulﬁlled the diagnosis criteria for hypopituitarism.
At the time of their second and ﬁnal visit (6± 0.2 months),
patients who remained with at least one aﬀected axis was
reduced to 56% (11/20). At the end of the study period, ﬁve
out of 20 patients (25%) fulﬁlled the criteria for hypopituita-
rism. In consequence, between their ﬁrst and second visit,
pituitary dynamic testing returned to normal in 35% of
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patients. The comparison of each pituitary axis is described
in Table 2.
Almost every patient who presented alteration of the
FSH/LH axis on the ﬁrst visit fully recovered at the second
visit (8/9). Of the patients who presented alteration in the
GH axis on their ﬁrst results, 26.6% had normal results on
their second visit (4/15). A total of 75% of the patients with
prolactin secretion impairment recovered its functionality
on their second visit. The patient with the TSH axis dysfunc-
tion remained altered on the second visit. Finally, of the ﬁve
patients with cortisol dysfunction at their ﬁrst visit, three
improved at their second assessment. Moreover, cortisol
dysfunction was addressed in another three patients, ending
with a total of ﬁve patients with ACTH axis deﬁciency.
When comparing mean peak hormonal axes values
between the ﬁrst and second hormone assessment, only
cortisol and GH had signiﬁcant statistical diﬀerences
between the groups (P < 0 0001 and P = 0 019, resp.) (data
not shown). After a detailed clinical history, none of the
women described any symptoms related to hypopituitarism
and every physical examination was unremarkable.
3.3. Clinical Factors Associated with Pituitary Dysfunction
Persistence after 6 Months. When comparing the baseline
characteristics of the event, there were no statistically
signiﬁcant risk factors associated with pituitary dysfunc-
tion development. However, a lower, but not signiﬁcant,
systolic blood pressure at the time of hypovolemic shock
was seen in patients with persisting pituitary dysfunction
(77.6± 17.28 versus 100.6± 24.63mmHg, P = 0 07) (Table 1).
3.4. Anti-Pituitary Antibodies. Serum from patients and
healthy subjects were tested on a PVDF membrane that
contained recombinant gamma enolase and protein lysates
Table 1: Demographic characteristics and clinical variables.
Characteristic Total Hypopituitarism Normal test
P value
Patients, n (%) n = 20 n = 5 n = 15
Age (years), mean (SD) 26.35 (±5.83) 26.40 (±5.94) 26.33 (±6.01) 0.951
Menarche (years), mean (SD) 11.9 (±1.20) 12.40 (±1.14) 11.73 (±1.22) 0.298
Previous hemorrhage, n (%) 1 (5) 0 (0) 1 (6.7) 0.554
Gravida, n (%)
1 7 (35) 0 (0) 7 (46.7) 0.077
2 6 (30) 3 (60) 3 (20)
≥3 7 (35) 2 (40) 5 (33.3)
Cesarean section, n (%) 9 (45) 1 (20) 8 (53.3) 0.319
Weeks of gestation, mean (SD) 38.16 (±2.29) 38.56 (±1.44) 38.02 (±2.56) 0.745
Hemorrhage etiology, n (%)
Uterine atony 13 (65) 3 (60) 10 (66.7) 0.285
Preeclampsia/eclampsia 1 (5) 0 (0) 1 (6.7)
Uterine rupture 1 (5) 1 (20) 0 (0)
Placenta previa 2 (10) 1 (20) 1 (6.7)
Vaginal tearing 3 (15) 0 (0) 3 (20)
Hysterectomy, n (%) 10 (50) 4 (80) 6 (40) 0.303
Hemorrhage (ml), mean (SD) 2070 (±1130.95) 2420 (±1247.79) 1953.33 (±1110.25) 0.439
Infused solutions (ml) 3363.15 (±1754.74) 4290 (±2237.85) 3032.14 (±1508) 0.176
RBC units (500ml each), mean (SD) 3.4 (±2.7) 4.6 (±3.3) 3.1 (±2.5) 0.284
Shock grade, n (%)
2 5 (25) 0 (0) 5 (33.3) 0.157
3 6 (30) 3 (60) 3 (20)
4 9 (45) 2 (40) 7 (46.7)
Shock index, mean (SD) 1.39 (±0.56) 1.74 (±0.53) 1.27 (±0.54) 0.113
Systolic BP, mean (SD) 94.9 (±24.79) 77.6 (±17.28) 100.66 (±24.63) 0.07
Diastolic BP, mean (SD) 58.1 (±18.00) 54.4 (±20.16) 59.33 (±17.81) 0.825
Heart rate, mean (SD) 120.65 (±20.60) 128.2 (±12.49) 118.13 (±22.45) 0.358
Time to stability (minutes), mean (SD) 74.21 (±28.34) 88.75 (±38.16) 70.33 (±25.38) 0.26
Hb preevent, mean (SD) 12.13 (±1.25) 12.1 (±0.58) 12.15 (±1.42) 0.938
Post Hb, mean (SD) 8.92 (±1.90) 10 (±2.13) 8.56 (±1.74) 0.148
Delta Hb, mean (SD) −3.217 (±2.10) −2.1 (±2.12) −3.58 (±2.02) 0.119
RBC: red blood cell; BP: blood pressure; Hb: hemoglobin.
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Table 2: Pituitary dynamic test results.
Patient
number






















1 1.97 2.53∗ 0.77 11.22 24.07∗ 0.17 0.17∗ <0.1 <0.1∗ 10.81 17.58 1.81 1.91∗
2 2.4 18.02 0.89 321.9 >470 0.15 0.17∗ <0.1 0.19∗ 13.46 21.18 0.97 0.76∗
3 1.15 10.39 1.2 12.94 159 4.84 59.33 4.61 16.08 15.63 11.62∗ 4.13 0.99∗
4 1.38 18.92 0.99 61.1 >470 0.19 0.23∗ 0.11 0.75 23.74 40.25 0.15 0.88∗
5 0.96 5.27 1.03 21.61 137.1 2.62 26.22 4.76 15.32 12.56 16.46∗ 7.87 6.36
6 3.05 15.4 0.9 334.9 >470 0.26 0.22∗ 0.13 0.16∗ 39.35 51.51 0.95 3.81∗
7 1.15 11.78 1.09 155.9 269.6∗ 0.2 0.21∗ 0.1 0.18∗ 30.35 40.27 1.42 18.3
8 5.3 28.8 1.07 228.6 >470 0.18 0.23∗ 0.21 0.51 62.9 62.8 0.39 0.38∗
9 1.86 6.59 1.14 83.94 297 0.29 0.82∗ 3.33 10.9 13.63 10.88∗ 0.33 0.84∗
10 0.42 3.6 1.6 65.5 269.9 0.2 0.3∗ 0.52 1.9 16.3 24.9 2.21 0.68∗
11 0.7 9.7 1.1 18.9 >470 0.22 0.35∗ 1.6 4.1 15.1 13.8∗ <0.05 0.18∗
12 1.6 8.5 1.22 39.5 97.1∗ 2.1 11.7 7.1 23.6 31.9 40.5 0.13 1.89∗
13 1.64 13.5 1.23 13.2 121.6 5.64 133.8 4.6 27.4 6.6 15.3 <0.05 0.42∗
14 1.7 11.3 1.39 80.1 >470 1.9 5.4∗ 6.1 16.2 28.3 33.7 0.68 20.7
15 1.3 11.9 1.3 84.1 188 9.6 86.8 5.6 17.4 16.6 26.8 0.14 4.4∗
16 2.59 12.72 1.15 104 171.5∗ 5.54 16.98 8.21 19.05 15.9 13.45∗ 0.37 0.32∗
17 0.8 8.07 1.38 31.72 217.4 5.46 23.78 6.6 16 14.7 18.16 2.3 3.25∗
18 0.93 30.9 1.13 175.5 444.8 4.61 44.79 10.68 39.53 10.83 17.26 0.2 2.3∗
19 2.22 26.06 0.9 141.6 >470 <0.1 <0.1∗ 0.49 1.49 18.9 37.4 0.42 5.69
20 2.2 14.1 1.06 11.6 120.2 3 112.7 3.9 29.5 22.4 24.9 3.64 21.4
Follow-up visit
1 1.82 3.48∗ 0.598 10.5 24.33∗ 6.09 12.51∗ 12.65 16.06 7.75 9.26∗ 0.077 0.453∗
2 1.7 12.7 1.12 10 61.6 9.9 74.2 2.9 8.3 11.8 8.4∗ 0.38 0.17∗
3 1.5 8.3 1.77 11.1 83.4 7.9 74.2 3.8 10.3 14.1 14.9∗ 3.1 0.26∗
4 1.34 21.15 1.15 12.48 69.48 1.1 25.43 2.2 17.09 9.02 17.6 0.05 4.67∗
5 0.88 8.9 1.18 4.3 38.4 3.5 46.6 2.8 9.1 11.9 24.8 7.5 6.6
6 1.5 12.9 1.4 15.7 104.3 7.1 70.4 4.9 12.8 30.4 33.5 8.7 10.1
7 0.72 6.1 1.6 32.5 82.2 10.3 >200 2.9 27.6 38.9 39.1 9.1 8.1
8 2.9 17.9 1.3 66.6 241.6 24.6 137.9 6.5 14.6 11.3 25.3 2.9 15.5
9 3.3 21.1 1.26 18.3 244.9 10 116.8 5.9 25.7 26.7 25.5 12.3 9.5
10 1.3 10.74 1.45 15 88.7 3.99 82.62 1.71 5.77 13.1 23.6 7.22 17.2
11 2.52 23.45 0.94 13.49 99.85 3.51 70.65 6.73 28.9 17.19 29.59 <0.05 3.69∗
12 1.07 9.74 1.26 32.76 115.7 12.77 140.5 4.68 13.26 12.9 38.4 0.11 7.83
13 1.16 9.02 1.19 11.44 48.38 9.52 44.72 4.48 9.31 9.49 16.27 0.14 0.56∗
14 2.89 14.24 1.23 51.27 144.7 2.23 23.9 5.03 12.24 22.53 22.87 <0.05 0.1∗
15 1.54 17.57 1.16 97.41 332.5 4.13 53.31 2.25 5.61 9.22 11.61∗ 2.21 2.23∗
16 15.25 >100 0.8 24.72 267.1 7.78 40.06 5.79 10.78 8.01 6.35∗ 0.11 0.15∗
17 0.89 10.64 1.27 16.8 92.25 6.04 19.65 6.51 9.37 13.37 22.68 0.46 4.8∗
18 2.3 14.9 1.3 10.5 90.8 4.4 60 3.6 8.6 9.5 20.1 2.28 6.99
19 2.6 26.2 1.18 13.8 122.9 4.3 35.7 2.9 8.7 13.9 25.9 0.1 3.26∗
20 1.95 12.7 1.19 8.25 101.2 12.52 160.3 5.3 14.3 28.3 28.71 3.16 9.14
TSH: thyroid-stimulating hormone; LH: luteinizing hormone; FSH: follicle-stimulating hormone; GH: growth hormone. The basal and highest values of each
hormonal axis assessed in the pituitary dynamic tests are shown. ∗Altered response to the pituitary dynamic test.
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from human hypophysis and from HEK-293 cells. In neither
patients nor controls, speciﬁc antibodies that recognized
protein bands were not detected, implying the absence of
anti-pituitary antibodies (Figure 1).
A nonspeciﬁc protein band of about 55 kDa was detected
on all the lanes with human pituitary’s protein lysates from
both patients and healthy subjects, which may correspond
to immunoglobulins present in the pituitary’s lysate sample.
3.5. Imaging Study. The ﬁve patients who fulﬁlled the criteria
for hypopituitarism underwent an enhancedMRI of the pitu-
itary gland two weeks after their second dynamic pituitary
test. None of the MRI studies revealed structural alterations
that could explain the patients’ altered pituitary function.
4. Discussion
In this prospective study, at six months follow-up, ﬁve out
of 20 pregnant women with PPH were found to have
hypopituitarism. Interestingly, all patients were asymptom-
atic and anti-pituitary antibodies were negative in all. In
addition, clinical characteristics and PPH factors were not
found to be associated with the risk of patients developing
Sheehan’s syndrome. To our knowledge, this is the largest
prospective study evaluating women’s risk of developing
Sheehan’s syndrome.
A few weeks after PPH, a higher proportion of hypopitu-
itarism (60%) was observed; however, only 25% of the
patients ended the study with hypopituitarism. This suggests
that after the event, there was a transient period of subclinical
pituitary dysfunction in 35% of the patients. In our study and
consistent with previous data, the GH axis was the most fre-
quent axis impaired (10/23). Interestingly, almost every
patient with FSH/LH axis dysfunction during the ﬁrst four
weeks recovered at the end of follow-up (eight out of nine).
However, only one third of the women with impaired GH
axis recovered (5/15). Even though there are several hypoth-
eses for this observation, the pathophysiology behind it
remains unclear; however, it is important to acknowledge
that FSH, LH, and GH have been reported to physiologically
decrease during pregnancy [19]. Of note, only the mean peak
GH and cortisol concentrations during the second visit were
diﬀerent among patients with hypopituitarism. Given that
GH was the most frequently impaired pituitary axis and cor-
tisol usually increases during pregnancy, a low basal cortisol
seems to predict its stimulated abnormality. Consequently,
these two pituitary axes seem to be the most important to
assess in patients with moderate to severe PPH.
Our results showed that after 6-7 months, the pituitary
impairments present during the ﬁrst four weeks after delivery
veered to improve in the majority of patients (58.33%). In
fact, there have been some case reports where patients with
Sheehan’s syndrome recover back to normal less than 1 year
after the event [20, 21]. Nevertheless, because pituitary func-
tion impairment in Sheehan’s syndrome can manifest after
several years, some of our patients may experience the
appearance of symptoms in future years [6, 22–24]. Our ﬁnd-
ings raise even more questions about the pathophysiology
behind Sheehan’s syndrome as it increases the conﬁdence
in the fact that hypoperfusion is not enough per se to
rationally explain the pathophysiology of the disease. Of
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Figure 1: Representative Western blot of human pituitary extracts. Serum samples from patients 16 and 20 (I, II) and healthy subjects (III)
were tested on recombinant gamma enolase (a), protein lysates from human pituitary (b), and HEK-293 cells (c). Arrowheads indicate a
nonspeciﬁc protein band of about 55 kDa which was seen on all lanes with human pituitary’s protein lysates, from both patients and
healthy subjects. MW: molecular weight marker.
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not receiving corticosteroids or any other hormonal supple-
mentation therapy before and during the study was carried
out. While the follow-up period was probably not long
enough for the development of symptoms, our ﬁndings
suggest that new recommendations, which may include
screening for pituitary dysfunction (with particular emphasis
on GH and cortisol axes) within the ﬁrst six months after a
moderate to severe PPH, might be needed. Moreover, previ-
ous studies had reported that some patients with Sheehan’s
syndrome present diabetes insipidus [25]. Nevertheless, none
of the patients in our study presented symptoms or labora-
tory ﬁndings suggestive of diabetes insipidus during the
study follow-up period (data not shown).
Recent studies suggest that autoimmunity plays a major
role in the pathophysiology of Sheehan’s syndrome. In fact,
De Bellis et al. found that an important proportion of
Sheehan’s syndrome patients (between three and 40 years
of evolution) had anti-pituitary and anti-hypothalamic anti-
bodies (35% and 40%, resp.). Despite these ﬁndings, it is
unclear if anti-pituitary and anti-hypothalamic antibodies
are the cause, enhancers, consequence of the disease, or silent
confounders. In our study, the follow-up was more than
enough for the appearance of autoantibodies; however, no
anti-pituitary antibodies were documented in any patient,
neither at four weeks nor during the following months after
delivery. This suggests that, in any case, autoantibodies in
Sheehan’s syndrome behave more as an enhancer of the
disease rather than an etiology factor. However, because of
the natural course of the disease, it is still plausible that
autoantibodies may be found many months or years after
the antigen exposition to the immune system and perpetuate
the hypopituitarism dysfunction, as previously reported
[15, 22–24]. Although Sheehan’s syndrome often presents
structural damage such as complete or partially empty
sella, we found a completely normal MRI in all the patients
[6, 22, 23]. We hypothesize that no structural alterations were
observed because theMRI evaluation in our study population
was done earlier in the course of the disease. This should be
assessed in future follow-up studies.
There are several limitations to our study. First, the
follow-up period was probably not enough to bring to light
the classical signs and symptoms of hypopituitarism. How-
ever, we think this is also a strength of the study due to the
fact that a prompt diagnosis enables on-time treatment that
can be oﬀered to the patient before clinical manifestations
of hypopituitarism impair their quality of life and potentially
threaten it. In addition, we will continue to follow in the next
years this cohort and will be able to report in the future their
biochemical and clinical behaviors. Second, IGF-1 and
ACTH values were not measured in this study. This could
generate doubts about the origin (i.e., primary or secondary)
of the impairments found. Nevertheless, because of the
nature of the disease, we considered that their measurements
were not necessary. However, we did use the gold standard
stimulation test (insulin-mediated hypoglycemia) for both
GH and cortisol. Third, there was a lack of a control group
in the study; however, there is strong data supporting the
notion that pituitary function remains unaltered during an
uncomplicated delivery. Fourth, probably, a larger sample
size and particularly a higher number of hypopituitarism
events could help uncover risk factors that can predict
the risk of hypopituitarism. However, our cohort is repre-
sentative of the average in our community, it is the largest
prospective study reported of its kind, and assessment of
exposure was through the use of secured medical records.
Finally, while it is plausible that other antibodies not mea-
sured in our study may play a role in the genesis of Sheehan’s
syndrome, to our knowledge, for the ﬁrst time in a prospec-
tive study, we assessed the most common anti-pituitary anti-
bodies described in the body of evidence.
5. Conclusion
In this prospective study of women with moderate to
severe PPH, one out of four was found to have, at six months
follow-up, asymptomatic nonautoimmune-mediated hypo-
pituitarism. Almost two-thirds of the patients with hypopitu-
itarism during the ﬁrst four weeks returned to normal at the
end of the study. None of the baseline clinical characteristics
was found to be associated with an increased risk of hypopi-
tuitarism. Further studies are needed to increase our knowl-
edge in the pathophysiology and presentation of this illness
that still aﬀects a considerable number of women and impairs
their health and quality of life.
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